BIOPSY NEEDLE FOR TUMOR BLOOD FLOW QUANTIFICATION

用于肿瘤血流定量的活检针

• 批准号: 6140517
• 负责人: GREGORY T MARTIN
• 金额: $ 37.18万
• 依托单位: THERMAL TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2002-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6140517
• 关键词: bioengineering /biomedical engineering; biomedical equipment development; biopsy; biosensor device; blood circulation; blood flow measurement; clinical biomedical equipment; computer program /software; computer simulation; fine needle aspiration; heat; laboratory rat; mathematical model; microprocessor /microchip; neoplasm /cancer blood supply; neoplasm /cancer therapy; phantom model; temperature; thermometry

This project seeks to incorporate blood flow (perfusion) sensors with core and aspiration biopsy needles. The feasibility of the integrated device was unambiguously demonstrated and validated in Phase I using the gold- standard microsphere technique in vivo. This device (needle, sensor, instrument and software) will serve as a tool to investigate the relationship between tumor blood flow/oxygenation and anti-tumor therapy outcome. Since perfusion is the carrier of oxygen which is a modifier of radiotherapy and chemotherapy, perfusion plays a significant role in the outcome of these therapies. There does not exist a tool to routinely assess tumor perfusion. This low cost device will provide information about the success of tumor blood flow modification agents, to help plan anti-tumor therapy for maximal effectiveness and to ensure that the biopsy is taken from diagnostic, non- necrotic tissue. Also it will collect perfusion data without increased patient morbidity nor increased risk for seeding the normal surrounding tissue with tumor cells over that of a standard biopsy procedure. In Phase II, biopsy perfusion probes will be designed and developed along with the controlling electronics and data analysis algorithms for use in a stand- alone computer/instrument. This entire system will be validated in a tumor model against the microsphere technique and the ability to modify tumor blood flow will be quantified. PROPOSED COMMERCIAL APPLICATION: The instrumented biopsy needle for the measurement of tumor blood flow has the potential to predict the efficacy of non-surgical anti-tumor therapy for hundreds of thousands of patients in the US each year. This device should find wide application in many research centers studying tumor blood flow in animal models and humans. A low-cost biopsy needle adjunct which quantifies tissue viability and tissue ischemia, and permits sensing of vessels in close proximity to the needle tip to aid in navigation, is expected to have great commercial potential.

该项目旨在将血流（灌注）传感器与核心和抽吸活检针相结合。在I期使用体内金标准微球技术明确证明和验证了集成装置的可行性。该器械（针头、传感器、仪器和软件）将作为研究肿瘤血流/氧合与抗肿瘤治疗结果之间关系的工具。由于灌注是氧的载体，氧是放疗和化疗的修饰剂，因此灌注在这些治疗的结果中起着重要作用。目前还不存在常规评估肿瘤灌注的工具。这种低成本设备将提供关于肿瘤血流调节剂的成功的信息，以帮助计划抗肿瘤治疗以获得最大效果，并确保活检取自诊断性非坏死组织。此外，它将收集灌注数据，而不会增加患者发病率，也不会增加标准活检程序中正常周围组织接种肿瘤细胞的风险。在第II阶段，将沿着设计和开发活检灌注探头以及用于独立计算机/仪器的控制电子器件和数据分析算法。整个系统将在肿瘤模型中验证微球技术，并量化改变肿瘤血流的能力。拟定商业应用：用于测量肿瘤血流的仪器化活检针有可能预测美国每年数十万患者的非手术抗肿瘤治疗的疗效。该装置应该在许多研究动物模型和人类肿瘤血流的研究中心中得到广泛应用。一种低成本的活检针附件，其量化组织活力和组织缺血，并允许感测靠近针尖的血管以帮助导航，预计具有很大的商业潜力。